https://www.businesswire.com/news/home/20230609005049/en/ImmunoGen-Presents-Updated-Findings-from-CADENZA-T
rial-of-Pivekimab-Sunirine-in-Blastic-Plasmacytoid-Dendritic-Cell-Neoplasm-at-EHA-2023-Congress?utm_
campaign=shareaholic&utm_medium=twitter&utm_source=socialnetwork


Efficacy
In frontline-treated patients including those with de novo and PCHM, the objective response rate (ORR [CR, CRc, CRh, CRi, PR]) is 80% (24/30 patients) with a composite complete remission (CCR [CR, CRc, CRh, CRi]) rate of 73% (22/30 patients), and an additional patient achieving a CR post-transplant.
Median duration of response (DOR) for all responders in frontline-treated patients was 12.7 months.